Venture Life Group PLC (LON:VLG)‘s stock had its “speculative buy” rating restated by Beaufort Securities in a research report issued on Thursday.

Separately, Panmure Gordon reissued a “buy” rating and issued a GBX 128 ($1.67) price target on shares of Venture Life Group PLC in a report on Friday, July 29th.

Venture Life Group PLC (LON:VLG) opened at 54.50 on Thursday. The company has a 50-day moving average of GBX 51.62 and a 200 day moving average of GBX 56.45. Venture Life Group PLC has a 12-month low of GBX 43.00 and a 12-month high of GBX 81.92. The firm’s market cap is GBX 18.75 million.

About Venture Life Group PLC

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.